Azilect Tablet
RxNorm Crosswalk NDC 68546-142

View RxNorm Concepts, RxCUIs, and Term Type mappings for this NDC

RxNorm Mapping Clinical Concepts

This drug is included in the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States.

The product Azilect (NDC 68546-142) is cross-mapped to the RxNorm terminology system to ensure clinical interoperability. This product is associated with 4 unique RxNorm concepts. By anchoring Teva Neuroscience, Inc.'s product data to these standardized identifiers, healthcare systems can maintain accurate medication records, safely automate e-prescribing, and streamline pharmacy workflows.

The following clinical concept cards detail the semantic term types (TTY), prescribable names, and synonymous clinical strings as defined by the National Library of Medicine (NLM).

SCD
Rasagiline 1 mg Oral Tablet
SCD
Rasagiline 0.5 mg Oral Tablet
PSN
Azilect 1 mg Oral Tablet
PSN
Azilect 0.5 mg Oral Tablet
SCDPrescribable
Featured Concept

rasagiline 1 MG Oral Tablet
(RxCUI 608328)

Semantic Clinical Drug

Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

Mapped Terms
PSNPrescribable
rasagiline 1 MG Oral Tablet
Prescribable Name
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.
SYPrescribable
rasagiline (as rasagiline mesylate) 1 MG Oral Tablet
Synonym
Synonym of another TTY, given for clarity.
SCDPrescribable
Featured Concept

rasagiline 0.5 MG Oral Tablet
(RxCUI 636664)

Semantic Clinical Drug

Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.

Mapped Terms
PSNPrescribable
rasagiline 0.5 MG Oral Tablet
Prescribable Name
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.
SYPrescribable
rasagiline (as rasagiline mesylate) 0.5 MG Oral Tablet
Synonym
Synonym of another TTY, given for clarity.
PSNPrescribable
Featured Concept

Azilect 1 MG Oral Tablet
(RxCUI 637185)

Prescribable Name

Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.

Mapped Terms
SBDPrescribable
rasagiline 1 MG Oral Tablet [Azilect]
Semantic Branded Drug
Ingredient + Strength + Dose Form + Brand Name
SYPrescribable
Azilect 1 MG (as rasagiline mesylate) Oral Tablet
Synonym
Synonym of another TTY, given for clarity.
SYPrescribable
Azilect 1 MG Oral Tablet
Synonym
Synonym of another TTY, given for clarity.
PSNPrescribable
Featured Concept

Azilect 0.5 MG Oral Tablet
(RxCUI 637218)

Prescribable Name

Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.

Mapped Terms
SBDPrescribable
rasagiline 0.5 MG Oral Tablet [Azilect]
Semantic Branded Drug
Ingredient + Strength + Dose Form + Brand Name
SYPrescribable
Azilect 0.5 MG Oral Tablet
Synonym
Synonym of another TTY, given for clarity.

Understanding RxNorm Mapping for Azilect

RxNorm is a normalized naming system developed by the National Library of Medicine (NLM) to bridge the gap between different drug terminologies. By mapping NDC 68546-142 to RxCUI 608328, 636664, 637185, 637218, this page provides the standardized "source of truth" required for hospital systems, e-prescribing software, and pharmacy benefit managers (PBMs) to communicate without errors.

Term Type (TTY) Legend for This Page

The clinical cards above utilize specific Term Types (TTY) to define the granularity of the drug concept:

  • PSN Prescribable Name: The standardized name preferred by electronic prescribing (eRx) applications for display.
  • SCD Semantic Clinical Drug: The clinical gold standard representing the Generic Name + Strength + Dosage Form.
  • SY Synonym: An alternative clinical name or alias provided for search and retrieval clarity.
  • SBD Semantic Branded Drug: The branded equivalent representing the Brand Name + Strength + Dosage Form.

* Please review the full disclaimer at the bottom of this page.